Akari Therapeutics (AKTX) Profit After Tax (2014 - 2026)
Akari Therapeutics (AKTX) reported Profit After Tax of -$14.5 million for Q1 2026, down 41200.0% on a YoY basis from N/an in Q1 2025, and down 195.48% sequentially from -$4.9 million in Q4 2025.
Akari Therapeutics (AKTX) Profit After Tax (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 10 years of Profit After Tax data on file, last reported at -$14.5 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 41200.0% year-over-year to -$14.5 million; the trailing twelve-month figure through Mar 2026 stood at -$21.3 million (up 85.88% YoY), and the FY2025 full-year result was -$17.3 million, down 5827.81% from the prior year.
- Profit After Tax slipped to -$14.5 million in Q1 2026, from -$4.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $1.0 million in Q1 2023 to a low of -$140.0 million in Q4 2024.
- A 4-year average of -$14.4 million and a median of -$4.0 million in 2023 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax jumped 99.37% in 2025 and tumbled 41200.0% in 2026, its largest moves.
- Tracing AKTX's Profit After Tax over 4 years: stood at -$4.1 million in 2023, then slumped by 3331.2% to -$140.0 million in 2024, then surged by 96.51% to -$4.9 million in 2025, then tumbled by 195.48% to -$14.5 million in 2026.
- Business Quant data shows AKTX's Profit After Tax at -$14.5 million in Q1 2026, -$4.9 million in Q4 2025, and -$38000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.46 Mn |
| Dec 31, 2025 | -4.89 Mn |
| Sep 30, 2025 | -38,000.00 |
| Jun 30, 2025 | -1.90 Mn |
| Mar 31, 2025 | -35,000.00 |
| Dec 31, 2024 | -139.99 Mn |
| Sep 30, 2024 | -3.07 Mn |
| Jun 30, 2024 | -7.56 Mn |
| Mar 31, 2024 | -5.57 Mn |
| Dec 31, 2023 | -4.08 Mn |
| Sep 30, 2023 | -2.87 Mn |
| Jun 30, 2023 | -4.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2020 | -6.84 Mn |
| Sep 30, 2020 | 909,778.00 |
| Jun 30, 2020 | -7.49 Mn |
| Mar 31, 2020 | -3.97 Mn |
| Dec 31, 2019 | 53,233.00 |
| Sep 30, 2019 | -2.88 Mn |
| Jun 30, 2019 | -6.11 Mn |